Repositorio Dspace

Listar por autor "Janssens, Stefan"

Listar por autor "Janssens, Stefan"

Ordenar por:Orden:Resultados:

  • Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial 
    Anker, Stefan D.; Butler, Javed; Filippatos, Gerasimos; Khan, Muhammad Shahzeb; Ferreira, João Pedro; Bocchi, Edimar; Böhm, Michael; Brunner-La Rocca, Hans Pieter; Choi, Dong-Ju; Chopra, Vijay; Chuquiure-Valenzuela, Eduardo; Giannetti, Nadia; Gomez-Mesa, Juan Esteban; Janssens, Stefan; Januzzi, James L.; Gonzalez-Juanatey, Jose R.; Merkely, Bela; Nicholls, Stephen J.; Perrone, Sergio Víctor; Piña, Ileana L.; Ponikowski, Piotr; Senni, Michele; Seronde, Marie-France; Sim, David; Spinar, Jindrich; Squire, Iain; Taddei, Stefano; Tsutsui, Hiroyuki; Verma, Subodh; Vinereanu, Dragos; Zhang, Jian; Jamal, Waheed; Schnaidt, Sven; Schnee, Janet; Brueckmann, Martina; Pocock, Stuart J.; Zannad, Faiez; Packer, Milton; EMPEROR-Preserved Trial Committees and Investigators (Wiley, 2020-12)
    Aims: EMPEROR-Preserved is an ongoing trial evaluating the effect of empagliflozin in patients with heart failure with preserved ejection fraction (HFpEF). This report describes the baseline characteristics of the ...
  • Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved 
    Anker, Stefan D.; Butler, Javed; Usman, Muhammad Shariq; Filippatos, Gerasimos; Ferreira, João Pedro; Bocchi, Edimar; Böhm, Michael; Brunner-La Rocca, Hans Pieter; Choi, Dong-Ju; Chopra, Vijay; Chuquiure, Eduardo; Giannetti, Nadia; Gomez-Mesa, Juan Esteban; Janssens, Stefan; Januzzi, James L.; González-Juanatey, José R.; Merkely, Bela; Nicholls, Stephen J.; Perrone, Sergio Víctor; Piña, Ileana L. (Nature Publishing Company, 2022-12)
    The EMPEROR-Preserved trial showed that the sodium-glucose co-transporter 2 inhibitor empagliflozin significantly reduces the risk of cardiovascular death or hospitalization for heart failure (HHF) in heart failure patients ...
  • Empagliflozin in Heart Failure with a Preserved Ejection Fraction 
    Anker, Stefan D.; Butler, Javed; Gerasimos, Filippatos; Ferreira, João Pedro; Bocchi, Edimar; Böhm, Michael; Brunner-La Rocca, Hans Pieter; Choi, Dong-Ju; Chopra, Vijay; Chuquiure-Valenzuela, Eduardo; Giannetti, Nadia; Gomez-Mesa, Juan Esteban; Janssens, Stefan; Januzzi, James L.; Gonzalez-Juanatey, Jose R.; Merkely, Bela; Nicholls, Stephen J.; Perrone, Sergio Víctor; Piña, Ileana L.; EMPEROR-Preserved Trial Investigators (Massachusetts Medical Society, 2021-08-27)
    Background: Sodium-glucose cotransporter 2 inhibitors reduce the risk of hospitalization for heart failure in patients with heart failure and a reduced ejection fraction, but their effects in patients with heart failure ...
  • Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared With Valsartan in HFpEF 
    Vaduganathan, Muthiah; Claggett, Brian L.; Desai, Akshay S.; Anker, Stefan D.; Perrone, Sergio Víctor; Janssens, Stefan; Milicic, Davor; Arango, Juan L.; Packer, Milton; Shi, Victor C.; Lefkowitz, Martin P.; McMurray, John J.V.; Solomon, Scott D. (Elsevier, 2020-01-28)
    Background: The period shortly after hospitalization for heart failure (HF) represents a high-risk window for recurrent clinical events, including rehospitalization or death. Objectives: This study sought to determine ...